MAINZ BIOMED NV (MYNZ)
NL0015000LC2 - Common Stock
We assign a fundamental rating of 2 out of 10 to MYNZ. MYNZ was compared to 568 industry peers in the Biotechnology industry. MYNZ may be in some trouble as it scores bad on both profitability and health. MYNZ is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
MYNZ had negative earnings in the past year.
In the past year MYNZ has reported a negative cash flow from operations.
In the past 5 years MYNZ always reported negative net income.
MYNZ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -311.04%, MYNZ is not doing good in the industry: 94.51% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -311.04% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYNZ has a better Gross Margin (56.91%) than 78.41% of its industry peers.
MYNZ's Gross Margin has improved in the last couple of years.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYNZ has more shares outstanding than it did 1 year ago.
MYNZ has a worse debt/assets ratio than last year.
2.2 Solvency
MYNZ has an Altman-Z score of -20.55. This is a bad value and indicates that MYNZ is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MYNZ (-20.55) is worse than 86.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.55 |
ROIC/WACCN/A
WACC6.4%
2.3 Liquidity
MYNZ has a Current Ratio of 0.24. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.
MYNZ's Current ratio of 0.24 is on the low side compared to the rest of the industry. MYNZ is outperformed by 96.46% of its industry peers.
MYNZ has a Quick Ratio of 0.24. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.19, MYNZ is not doing good in the industry: 96.99% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.24 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
MYNZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.96%, which is quite good.
MYNZ shows a strong growth in Revenue. In the last year, the Revenue has grown by 68.96%.
Measured over the past years, MYNZ shows a very strong growth in Revenue. The Revenue has been growing by 22.26% on average per year.
EPS 1Y (TTM)12.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.32%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%109.99%
3.2 Future
MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.58% yearly.
The Revenue is expected to grow by 156.06% on average over the next years. This is a very strong growth
EPS Next Y45.58%
EPS Next 2Y24.09%
EPS Next 3Y16.86%
EPS Next 5Y14.58%
Revenue Next Year27.57%
Revenue Next 2Y56.37%
Revenue Next 3Y113.85%
Revenue Next 5Y156.07%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MYNZ's earnings are expected to grow with 16.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.09%
EPS Next 3Y16.86%
5. Dividend
5.1 Amount
MYNZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MAINZ BIOMED NV
NASDAQ:MYNZ (12/20/2024, 8:26:23 PM)
After market: 6.9 +0.22 (+3.29%)6.68
+1.91 (+40.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.76M
Analysts45.71
Price Target2.04 (-69.46%)
Short Float %N/A
Short Ratio1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)13.33%
EPS NQ rev (3m)13.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-47.37%
Revenue NQ rev (3m)-47.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.64
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-10.53
FCFYN/A
OCF(TTM)-10.11
OCFYN/A
SpS0.47
BVpS-2.17
TBVpS-3.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -311.04% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.91% | ||
| FCFM | N/A |
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 88.5% | ||
| Cap/Sales | 89.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.24 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z | -20.55 |
F-Score3
WACC6.4%
ROIC/WACCN/A
Cap/Depr(3y)140.47%
Cap/Depr(5y)87.62%
Cap/Sales(3y)113.34%
Cap/Sales(5y)68.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.32%
EPS Next Y45.58%
EPS Next 2Y24.09%
EPS Next 3Y16.86%
EPS Next 5Y14.58%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%109.99%
Revenue Next Year27.57%
Revenue Next 2Y56.37%
Revenue Next 3Y113.85%
Revenue Next 5Y156.07%
EBIT growth 1Y-0.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-104.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.2%
OCF growth 3YN/A
OCF growth 5YN/A